101-PGC-005

DRUG2 trials

Sponsors

101 Therapeutics

Conditions

COVID-19Glucocorticoids ToxicityInfectious DiseaseVirus Diseases

Phase 1

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

101 TherapeuticsCOVID-19, Glucocorticoids Toxicity, Infectious Disease +1

Start: 2022-10-29End: 2023-01-15Updated: 2022-12-14

Phase 2

101-PGC-005 for the Treatment of COVID-19

101 TherapeuticsCOVID-19

Start: 2023-01-31End: 2023-06-30Updated: 2023-05-30